Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Moyamoya disease: Etiology, clinical features, and diagnosis

Nijasri Charnnarong Suwanwela, MD
Section Editors
Jose Biller, MD, FACP, FAAN, FAHA
Douglas R Nordli, Jr, MD
Deputy Editor
John F Dashe, MD, PhD


Moyamoya disease (MMD) is a unique chronic progressive cerebrovascular disease characterized by bilateral stenosis or occlusion of the arteries around the circle of Willis with prominent arterial collateral circulation. "Moyamoya" is a Japanese word meaning puffy, obscure, or hazy like a puff of smoke in the air. Thus, the term was used to describe the smoky angiographic appearance of the vascular collateral network [1,2].

Moyamoya disease was first described in Japan in 1957. Many similar cases have subsequently been reported, mainly in Japan and other Asian countries. The disease is found less frequently in North America and Europe.

This topic will review the etiology and clinical aspects of moyamoya disease. Prognosis and treatment are discussed elsewhere. (See "Moyamoya disease: Treatment and prognosis".)


The etiology of MMD is unknown. The high incidence among the Japanese and Asian population, together with a familial occurrence of approximately 10 to 15 percent of cases, strongly suggests a genetic etiology.

Accumulating evidence suggests that the RNF213 gene on chromosome 17q25.3 is an important susceptibility factor for MMD in East Asian populations [3-8].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Sep 12, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Suzuki J, Kodama N. Moyamoya disease--a review. Stroke 1983; 14:104.
  2. Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969; 20:288.
  3. Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet 2011; 56:34.
  4. Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 2011; 6:e22542.
  5. Miyatake S, Miyake N, Touho H, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology 2012; 78:803.
  6. Yamauchi T, Tada M, Houkin K, et al. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 2000; 31:930.
  7. Mineharu Y, Liu W, Inoue K, et al. Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology 2008; 70:2357.
  8. Miyawaki S, Imai H, Takayanagi S, et al. Identification of a genetic variant common to moyamoya disease and intracranial major artery stenosis/occlusion. Stroke 2012; 43:3371.
  9. Wu Z, Jiang H, Zhang L, et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One 2012; 7:e48179.
  10. Bang OY, Ryoo S, Kim SJ, et al. Adult Moyamoya Disease: A Burden of Intracranial Stenosis in East Asians? PLoS One 2015; 10:e0130663.
  11. Ikeda H, Sasaki T, Yoshimoto T, et al. Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 1999; 64:533.
  12. Inoue TK, Ikezaki K, Sasazuki T, et al. Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 2000; 15:179.
  13. Sakurai K, Horiuchi Y, Ikeda H, et al. A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 2004; 49:278.
  14. Mineharu Y, Takenaka K, Yamakawa H, et al. Inheritance pattern of familial moyamoya disease: autosomal dominant mode and genomic imprinting. J Neurol Neurosurg Psychiatry 2006; 77:1025.
  15. Inoue TK, Ikezaki K, Sasazuki T, et al. Analysis of class II genes of human leukocyte antigen in patients with moyamoya disease. Clin Neurol Neurosurg 1997; 99 Suppl 2:S234.
  16. Suzui H, Hoshimaru M, Takahashi JA, et al. Immunohistochemical reactions for fibroblast growth factor receptor in arteries of patients with moyamoya disease. Neurosurgery 1994; 35:20.
  17. Malek AM, Connors S, Robertson RL, et al. Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg 1997; 27:182.
  18. Yamamoto M, Aoyagi M, Tajima S, et al. Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke 1997; 28:1733.
  19. Hojo M, Hoshimaru M, Miyamoto S, et al. Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg 1998; 89:623.
  20. Nanba R, Kuroda S, Ishikawa T, et al. Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke 2004; 35:2837.
  21. Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39:2644.
  22. Lee S, Rivkin MJ, Kirton A, et al. Moyamoya Disease in Children: Results From the International Pediatric Stroke Study. J Child Neurol 2017; 32:924.
  23. Lee SJ, Ahn JY. Stenosis of the proximal external carotid artery in an adult with moyamoya disease: moyamoya or atherosclerotic change? Neurol Med Chir (Tokyo) 2007; 47:356.
  24. Czartoski T, Hallam D, Lacy JM, et al. Postinfectious vasculopathy with evolution to moyamoya syndrome. J Neurol Neurosurg Psychiatry 2005; 76:256.
  25. Yamada H, Deguchi K, Tanigawara T, et al. The relationship between moyamoya disease and bacterial infection. Clin Neurol Neurosurg 1997; 99 Suppl 2:S221.
  26. Sharfstein SR, Ahmed S, Islam MQ, et al. Case of moyamoya disease in a patient with advanced acquired immunodeficiency syndrome. J Stroke Cerebrovasc Dis 2007; 16:268.
  27. Hammond CK, Shapson-Coe A, Govender R, et al. Moyamoya Syndrome in South African Children With HIV-1 Infection. J Child Neurol 2016; 31:1010.
  28. Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol 2003; 29:124.
  29. Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 2002; 99:3144.
  30. Kirkham FJ, DeBaun MR. Stroke in Children with Sickle Cell Disease. Curr Treat Options Neurol 2004; 6:357.
  31. Marden FA, Putman CM, Grant JM, Greenberg J. Moyamoya disease associated with hemoglobin Fairfax and beta-thalassemia. Pediatr Neurol 2008; 38:130.
  32. Pavlakis SG, Verlander PC, Gould RJ, et al. Fanconi anemia and moyamoya: evidence for an association. Neurology 1995; 45:998.
  33. Tokunaga Y, Ohga S, Suita S, et al. Moyamoya syndrome with spherocytosis: effect of splenectomy on strokes. Pediatr Neurol 2001; 25:75.
  34. Cerrato P, Grasso M, Lentini A, et al. Atherosclerotic adult Moya-Moya disease in a patient with hyperhomocysteinaemia. Neurol Sci 2007; 28:45.
  35. Dhopesh VP, Dunn DP, Schick P. Moyamoya and Hageman factor (Factor XII) deficiency in a black adult. Arch Neurol 1978; 35:396.
  36. Kornblihtt LI, Cocorullo S, Miranda C, et al. Moyamoya syndrome in an adolescent with essential thrombocythemia: successful intracranial carotid stent placement. Stroke 2005; 36:E71.
  37. Wang R, Xu Y, Lv R, Chen J. Systemic lupus erythematosus associated with Moyamoya syndrome: a case report and literature review. Lupus 2013; 22:629.
  38. Kendall B. Cerebral angiography in vasculitis affecting the nervous system. Eur Neurol 1984; 23:400.
  39. Sasaki T, Nogawa S, Amano T. Co-morbidity of moyamoya disease with Graves' disease. report of three cases and a review of the literature. Intern Med 2006; 45:649.
  40. Im SH, Oh CW, Kwon OK, et al. Moyamoya disease associated with Graves disease: special considerations regarding clinical significance and management. J Neurosurg 2005; 102:1013.
  41. Kushima K, Satoh Y, Ban Y, et al. Graves' thyrotoxicosis and Moyamoya disease. Can J Neurol Sci 1991; 18:140.
  42. Bower RS, Mallory GW, Nwojo M, et al. Moyamoya disease in a primarily white, midwestern US population: increased prevalence of autoimmune disease. Stroke 2013; 44:1997.
  43. Carhuapoma JR, D'Olhaberriague L, Levine SR. Moyamoya syndrome associated with Sneddon's syndrome and antiphospholipid-protein antibodies. J Stroke Cerebrovasc Dis 1999; 8:51.
  44. Bonduel M, Hepner M, Sciuccati G, et al. Prothrombotic disorders in children with moyamoya syndrome. Stroke 2001; 32:1786.
  45. Provost TT, Moses H, Morris EL, et al. Cerebral vasculopathy associated with collateralization resembling moya moya phenomenon and with anti-Ro/SS-A and anti-La/SS-B antibodies. Arthritis Rheum 1991; 34:1052.
  46. Khan M, Novakovic RL, Rosengart AJ. Intraventricular hemorrhage disclosing neurofibromatosis 1 and moyamoya phenomena. Arch Neurol 2006; 63:1653.
  47. Horikawa M, Utunomiya H, Hirotaka S, et al. Case of von Recklinghausen disease associated with cerebral infarction. J Child Neurol 1997; 12:144.
  48. Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 2005; 64:553.
  49. Imaizumi M, Nukada T, Yoneda S, et al. Tuberous sclerosis with moyamoya disease. Case report. Med J Osaka Univ 1978; 28:345.
  50. Garcia JC, Roach ES, McLean WT. Recurrent thrombotic deterioration in the Sturge-Weber syndrome. Childs Brain 1981; 8:427.
  51. Tsuruta D, Fukai K, Seto M, et al. Phakomatosis pigmentovascularis type IIIb associated with moyamoya disease. Pediatr Dermatol 1999; 16:35.
  52. Rafay MF, Al-Futaisi A, Weiss S, Armstrong D. Hypomelanosis of Ito and Moyamoya disease. J Child Neurol 2005; 20:924.
  53. Meyer S, Zanardo L, Kaminski WE, et al. Elastosis perforans serpiginosa-like pseudoxanthoma elasticum in a child with severe Moya Moya disease. Br J Dermatol 2005; 153:431.
  54. Terada T, Yokote H, Tsuura M, et al. Marfan syndrome associated with moyamoya phenomenon and aortic dissection. Acta Neurochir (Wien) 1999; 141:663.
  55. Jea A, Smith ER, Robertson R, Scott RM. Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization. Pediatrics 2005; 116:e694.
  56. de Borchgrave V, Saussu F, Depre A, de Barsy T. Moyamoya disease and Down syndrome: case report and review of the literature. Acta Neurol Belg 2002; 102:63.
  57. Spengos K, Kosmaidou-Aravidou Z, Tsivgoulis G, et al. Moyamoya syndrome in a Caucasian woman with Turner's syndrome. Eur J Neurol 2006; 13:e7.
  58. Kamath BM, Spinner NB, Emerick KM, et al. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation 2004; 109:1354.
  59. Rocha R, Soro I, Leitão A, et al. Moyamoya vascular pattern in Alagille syndrome. Pediatr Neurol 2012; 47:125.
  60. Takeuchi K, Hara M, Yokota H, et al. Factors influencing the development of Moyamoya phenomenon. Acta Neurochir (Wien) 1981; 59:79.
  61. Ullrich NJ, Robertson R, Kinnamon DD, et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 2007; 68:932.
  62. de Vries RR, Nikkels PG, van der Laag J, et al. Moyamoya and extracranial vascular involvement: fibromuscular dysplasia? A report of two children. Neuropediatrics 2003; 34:318.
  63. Lutterman J, Scott M, Nass R, Geva T. Moyamoya syndrome associated with congenital heart disease. Pediatrics 1998; 101:57.
  64. Kawai M, Nishikawa T, Tanaka M, et al. An autopsied case of Williams syndrome complicated by moyamoya disease. Acta Paediatr Jpn 1993; 35:63.
  65. Christiaens FJ, Van den Broeck LK, Christophe C, Dan B. Moyamoya disease (moyamoya syndrome) and coarctation of the aorta. Neuropediatrics 2000; 31:47.
  66. Yamada I, Himeno Y, Matsushima Y, Shibuya H. Renal artery lesions in patients with moyamoya disease: angiographic findings. Stroke 2000; 31:733.
  67. Sunder TR. Moyamoya disease in a patient with type I glycogenosis. Arch Neurol 1981; 38:251.
  68. Goutières F, Bourgeois M, Trioche P, et al. Moyamoya disease in a child with glycogen storage disease type Ia. Neuropediatrics 1997; 28:133.
  69. Tokuç G, Minareci O, Yavuzer D, et al. Moya Moya syndrome in a child with hyperphosphatasia. Pediatr Int 1999; 41:399.
  70. Lammie GA, Wardlaw J, Dennis M. Thrombo-embolic stroke, moya-moya phenomenon and primary oxalosis. Cerebrovasc Dis 1998; 8:45.
  71. Fernandez-Alvarez E, Pineda M, Royo C, Manzanares R. "Moya-moya' disease caused by cranial trauma. Brain Dev 1979; 1:133.
  72. Kitano S, Sakamoto H, Fujitani K, Kobayashi Y. Moyamoya disease associated with a brain stem glioma. Childs Nerv Syst 2000; 16:251.
  73. Arita K, Uozumi T, Oki S, et al. Moyamoya disease associated with pituitary adenoma--report of two cases. Neurol Med Chir (Tokyo) 1992; 32:753.
  74. Tsuji N, Kuriyama T, Iwamoto M, Shizuki K. Moyamoya disease associated with craniopharyngioma. Surg Neurol 1984; 21:588.
  75. Korematsu K, Yoshioka S, Maruyama T, et al. De novo appearance of cerebellar cavernous malformation in a patient with moyamoya disease: case report and review of the literature. Clin Neurol Neurosurg 2007; 109:708.
  76. Kim JS, No YJ. Moyamoya-like vascular abnormality in pulmonary sarcoidosis. Cerebrovasc Dis 2006; 22:71.
  77. Takenaka K, Ito M, Kumagai M, et al. Moyamoya disease associated with pulmonary sarcoidosis--case report. Neurol Med Chir (Tokyo) 1998; 38:566.
  78. Hervé D, Touraine P, Verloes A, et al. A hereditary moyamoya syndrome with multisystemic manifestations. Neurology 2010; 75:259.
  79. Pracyk JB, Massey JM. Moyamoya disease associated with polycystic kidney disease and eosinophilic granuloma. Stroke 1989; 20:1092.
  80. Nzwalo H, Santos V, Gradil C, et al. Caucasian familial moyamoya syndrome with rare multisystemic malformations. Pediatr Neurol 2013; 48:240.
  81. Peerless SJ. Risk factors of moyamoya disease in Canada and the USA. Clin Neurol Neurosurg 1997; 99 Suppl 2:S45.
  82. Wakai K, Tamakoshi A, Ikezaki K, et al. Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg 1997; 99 Suppl 2:S1.
  83. Kuriyama S, Kusaka Y, Fujimura M, et al. Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke 2008; 39:42.
  84. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 2008; 79:900.
  85. Uchino K, Johnston SC, Becker KJ, Tirschwell DL. Moyamoya disease in Washington State and California. Neurology 2005; 65:956.
  86. Amlie-Lefond C, Zaidat OO, Lew SM. Moyamoya disease in early infancy: case report and literature review. Pediatr Neurol 2011; 44:299.
  87. Al-Yassin A, Saunders DE, Mackay MT, Ganesan V. Early-onset bilateral cerebral arteriopathies: Cohort study of phenotype and disease course. Neurology 2015; 85:1146.
  88. Duan L, Bao XY, Yang WZ, et al. Moyamoya disease in China: its clinical features and outcomes. Stroke 2012; 43:56.
  89. Kleinloog R, Regli L, Rinkel GJ, Klijn CJ. Regional differences in incidence and patient characteristics of moyamoya disease: a systematic review. J Neurol Neurosurg Psychiatry 2012; 83:531.
  90. Kitamura K, Fukui M, Oka K. Moyamoya disease. In: Handbook of Clinical Neurology, Elsevier, Amsterdam, 1989. Vol 2, p.293.
  91. Nah HW, Kwon SU, Kang DW, et al. Moyamoya disease-related versus primary intracerebral hemorrhage: [corrected] location and outcomes are different. Stroke 2012; 43:1947.
  92. Kraemer M, Heienbrok W, Berlit P. Moyamoya disease in Europeans. Stroke 2008; 39:3193.
  93. Zafar SF, Bershad EM, Gildersleeve KL, et al. Adult moyamoya disease in an urban center in the United States is associated with a high burden of watershed ischemia. J Am Heart Assoc 2014; 3.
  94. Choi JU, Kim DS, Kim EY, Lee KC. Natural history of moyamoya disease: comparison of activity of daily living in surgery and non surgery groups. Clin Neurol Neurosurg 1997; 99 Suppl 2:S11.
  95. Hung CC, Tu YK, Su CF, et al. Epidemiological study of moyamoya disease in Taiwan. Clin Neurol Neurosurg 1997; 99 Suppl 2:S23.
  96. Battistella PA, Carollo C. Clinical and neuroradiological findings of moyamoya disease in Italy. Clin Neurol Neurosurg 1997; 99 Suppl 2:S54.
  97. Li JY, Lai PH, Peng NJ. Moyamoya disease presenting with hemichoreoathetosis and hemidystonia. Mov Disord 2007; 22:1983.
  98. Kim YO, Kim TS, Woo YJ, et al. Moyamoya disease-induced hemichorea corrected by indirect bypass surgery. Pediatr Int 2006; 48:504.
  99. Baik JS, Lee MS. Movement disorders associated with moyamoya disease: a report of 4 new cases and a review of literatures. Mov Disord 2010; 25:1482.
  100. Quah BL, Hamilton J, Blaser S, et al. Morning glory disc anomaly, midline cranial defects and abnormal carotid circulation: an association worth looking for. Pediatr Radiol 2005; 35:525.
  101. Komiyama M, Yasui T, Sakamoto H, et al. Basal meningoencephalocele, anomaly of optic disc and panhypopituitarism in association with moyamoya disease. Pediatr Neurosurg 2000; 33:100.
  102. Krishnan C, Roy A, Traboulsi E. Morning glory disk anomaly, choroidal coloboma, and congenital constrictive malformations of the internal carotid arteries (moyamoya disease). Ophthalmic Genet 2000; 21:21.
  103. Kodama N, Aoki Y, Hiraga H, et al. Electroencephalographic findings in children with moyamoya disease. Arch Neurol 1979; 36:16.
  104. Cho A, Chae JH, Kim HM, et al. Electroencephalography in pediatric moyamoya disease: reappraisal of clinical value. Childs Nerv Syst 2014; 30:449.
  105. Smith ER. Moyamoya arteriopathy. Curr Treat Options Neurol 2012; 14:549.
  106. Kim HY, Chung CS, Lee J, et al. Hyperventilation-induced limb shaking TIA in Moyamoya disease. Neurology 2003; 60:137.
  107. Spengos K, Tsivgoulis G, Toulas P, et al. Hyperventilation-enhanced chorea as a transient ischaemic phenomenon in a patient with moyamoya disease. Eur Neurol 2004; 51:172.
  108. Bakdash T, Cohen AR, Hempel JM, et al. Moyamoya, dystonia during hyperventilation, and antiphospholipid antibodies. Pediatr Neurol 2002; 26:157.
  109. Frechette ES, Bell-Stephens TE, Steinberg GK, Fisher RS. Electroencephalographic features of moyamoya in adults. Clin Neurophysiol 2015; 126:481.
  110. Kim JM, Lee SH, Roh JK. Changing ischaemic lesion patterns in adult moyamoya disease. J Neurol Neurosurg Psychiatry 2009; 80:36.
  111. Takahashi M, Miyauchi T, Kowada M. Computed tomography of Moyamoya disease: demonstration of occluded arteries and collateral vessels as important diagnostic signs. Radiology 1980; 134:671.
  112. Handa J, Nakano Y, Okuno T, et al. Computerized tomography in Moyamoya syndrome. Surg Neurol 1977; 7:315.
  113. Rafay MF, Armstrong D, Dirks P, et al. Patterns of cerebral ischemia in children with moyamoya. Pediatr Neurol 2015; 52:65.
  114. Kikuta K, Takagi Y, Nozaki K, et al. Asymptomatic microbleeds in moyamoya disease: T2*-weighted gradient-echo magnetic resonance imaging study. J Neurosurg 2005; 102:470.
  115. Kikuta K, Takagi Y, Nozaki K, et al. The presence of multiple microbleeds as a predictor of subsequent cerebral hemorrhage in patients with moyamoya disease. Neurosurgery 2008; 62:104.
  116. Kuroda S, Kashiwazaki D, Ishikawa T, et al. Incidence, locations, and longitudinal course of silent microbleeds in moyamoya disease: a prospective T2*-weighted MRI study. Stroke 2013; 44:516.
  117. Ohta T, Tanaka H, Kuroiwa T. Diffuse leptomeningeal enhancement, "ivy sign," in magnetic resonance images of moyamoya disease in childhood: case report. Neurosurgery 1995; 37:1009.
  118. Maeda M, Tsuchida C. "Ivy sign" on fluid-attenuated inversion-recovery images in childhood moyamoya disease. AJNR Am J Neuroradiol 1999; 20:1836.
  119. Chung PW, Park KY. Leptomeningeal enhancement in petients with moyamoya disease: correlation with perfusion imaging. Neurology 2009; 72:1872.
  120. Mori N, Mugikura S, Higano S, et al. The leptomeningeal "ivy sign" on fluid-attenuated inversion recovery MR imaging in Moyamoya disease: a sign of decreased cerebral vascular reserve? AJNR Am J Neuroradiol 2009; 30:930.
  121. Ryoo S, Cha J, Kim SJ, et al. High-resolution magnetic resonance wall imaging findings of Moyamoya disease. Stroke 2014; 45:2457.
  122. Hasuo K, Mihara F, Matsushima T. MRI and MR angiography in moyamoya disease. J Magn Reson Imaging 1998; 8:762.
  123. Yamada I, Nakagawa T, Matsushima Y, Shibuya H. High-resolution turbo magnetic resonance angiography for diagnosis of Moyamoya disease. Stroke 2001; 32:1825.
  124. Tsuchiya K, Makita K, Furui S. Moyamoya disease: diagnosis with three-dimensional CT angiography. Neuroradiology 1994; 36:432.
  125. Takase K, Kashihara M, Hashimoto T. Transcranial Doppler ultrasonography in patients with moyamoya disease. Clin Neurol Neurosurg 1997; 99 Suppl 2:S101.
  126. Lee YS, Jung KH, Roh JK. Diagnosis of moyamoya disease with transcranial Doppler sonography: correlation study with magnetic resonance angiography. J Neuroimaging 2004; 14:319.
  127. Takeuchi S, Tanaka R, Ishii R, et al. Cerebral hemodynamics in patients with moyamoya disease. A study of regional cerebral blood flow by the 133Xe inhalation method. Surg Neurol 1985; 23:468.
  128. Ikezaki K, Matsushima T, Kuwabara Y, et al. Cerebral circulation and oxygen metabolism in childhood moyamoya disease: a perioperative positron emission tomography study. J Neurosurg 1994; 81:843.
  129. Nambu K, Suzuki R, Hirakawa K. Cerebral blood flow: measurement with xenon-enhanced dynamic helical CT. Radiology 1995; 195:53.
  130. Shirane R, Yoshida Y, Takahashi T, Yoshimoto T. Assessment of encephalo-galeo-myo-synangiosis with dural pedicle insertion in childhood moyamoya disease: characteristics of cerebral blood flow and oxygen metabolism. Clin Neurol Neurosurg 1997; 99 Suppl 2:S79.
  131. Khan N, Yonekawa Y. Moyamoya angiopathy in Europe. Acta Neurochir Suppl 2005; 94:149.
  132. Tanaka Y, Nariai T, Nagaoka T, et al. Quantitative evaluation of cerebral hemodynamics in patients with moyamoya disease by dynamic susceptibility contrast magnetic resonance imaging--comparison with positron emission tomography. J Cereb Blood Flow Metab 2006; 26:291.
  133. Oka K, Yamashita M, Sadoshima S, Tanaka K. Cerebral haemorrhage in Moyamoya disease at autopsy. Virchows Arch A Pathol Anat Histol 1981; 392:247.
  134. Morgenlander JC, Goldstein LB. Recurrent transient ischemic attacks and stroke in association with an internal carotid artery web. Stroke 1991; 22:94.
  135. Carlson CB, Harvey FH, Loop J. Progressive alternating hemiplegia in early childhood and basal arterial stenosis and telangiectasia (moyamoya syndrome). Neurology 1973; 23:734.
  136. Yamashita M, Oka K, Tanaka K. Histopathology of the brain vascular network in moyamoya disease. Stroke 1983; 14:50.
  137. Hosoda Y. Pathology of so-called "spontaneous occlusion of the circle of Willis". Pathol Annu 1984; 19 Pt 2:221.
  138. Hosoda Y, Ikeda E, Hirose S. Histopathological studies on spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease). Clin Neurol Neurosurg 1997; 99 Suppl 2:S203.
  139. Takagi Y, Kikuta K, Nozaki K, Hashimoto N. Histological features of middle cerebral arteries from patients treated for Moyamoya disease. Neurol Med Chir (Tokyo) 2007; 47:1.
  140. Kodama N, Fujiwara S, Horie Y, et al. [Transdural anastomosis in moyamoya disease--vault moyamoy (author's transl)]. No Shinkei Geka 1980; 8:729.
  141. Kodama N, Suzuki J. Moyamoya disease associated with aneurysm. J Neurosurg 1978; 48:565.
  142. Adams HP Jr, Kassell NF, Wisoff HS, Drake CG. Intracranial saccular aneurysm and moyamoya disease. Stroke 1979; 10:174.
  143. Nagamine Y, Takahashi S, Sonobe M. Multiple intracranial aneurysms associated with moyamoya disease. Case report. J Neurosurg 1981; 54:673.
  144. Yabumoto M, Funahashi K, Fujii T, et al. Moyamoya disease associated with intracranial aneurysms. Surg Neurol 1983; 20:20.
  145. Konishi Y, Kadowaki C, Hara M, Takeuchi K. Aneurysms associated with moyamoya disease. Neurosurgery 1985; 16:484.
  146. Herreman F, Nathal E, Yasui N, et al. Intracranial aneurysm in moyamoya disease: report of ten cases and review of the literature. Cerebrovasc Dis 1994; 4:329.
  147. Goldstein M, Hanquinet P, Couvreur Y. [A case of fibromuscular dysplasia in an unusual location]. Acta Chir Belg 1984; 84:345.
  148. Ikeda E. Systemic vascular changes in spontaneous occlusion of the circle of Willis. Stroke 1991; 22:1358.
  149. Togao O, Mihara F, Yoshiura T, et al. Prevalence of stenoocclusive lesions in the renal and abdominal arteries in moyamoya disease. AJR Am J Roentgenol 2004; 183:119.
  150. Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg 1997; 99 Suppl 2:S238.